Observations and Debates on China's Recent Healthcare Reforms  
 

The European Union Chamber of Commerce in China and China Europe International Business School (CEIBS) are delighted to invite you to an afternoon forum on China’s new Healthcare Reform on Tuesday 8th September.

Earlier this year the Chinese government vowed to invest a total of 850 billion RMB to reform its ailing healthcare sector over the next three years, kicking off a much-anticipated reform that aims towards providing "safe, effective, convenient and affordable" health services to all 1.3 billion residents by 2020.

New business opportunities will be created in China's pharmaceutical and medical device sector, together with new challenges that would reshape the general operating environment by a reform intending to bring about structural as well as mindset changes to the concept of health care.

At this forum, our guest specialists will share with you a 360-degree deep insight into China's aggressive plan to revamp its health-care system new blueprint to a universal healthcare system by highlighting the opportunities and challenges to foreign enterprises, and by giving key information to attendees to drive successful strategies and operations in developing business in China.

 Topics

1. Health care reform and implications for Business
by Professor Zhang Wei from CEIBS

China has launched its ambitious health care reform aiming to provide universal coverage, but policy ambition has to compromise with budget and capacity constrain. Dr. Zhang will review the rationales and goals of the current reform from a system perspective, and focus on the three key elements of access, cost and quality.  He will argue that “improving the coverage” should not overshadow the more important task of “improving the care”, and that health care reform should be value-based, instead of cost-centered. 

2. Unlocking China‘s Medical Device Market Potential Brought by the Chinese Healthcare Reform
by Mr. Glenn Hou, Consulting Director China, Healthcare, Frost & Sullivan

China Healthcare Reform has brought various impacts on Medical Technology industry.  Mr. Hou will bring a discussion on the current status of the Healthcare Reform and its impact on the medical technology industry, and finally some case studies of how local and multi-national companies grab the opportunities brought by the reform.

3. Medical Device Pricing Reform - Is it the Next?
by Mr. Camon Sin, Director, Healthcare Economics, Greater China, Medtronic

There is specific address of the price formation mechanism in the Healthcare Reform Plan released in April 2009.  With the determination in expanding the social medical insurance to cover basically the entire population, will the Chinese government as the biggest payer of medical expenses put more effort in controlling the price of drugs and medical devices?  The recent activities in preparing for the essential drugs supply suggest that price is one of the key focuses in the reform development.  What are the likely next steps of the Chinese government after releasing the NDRC consultation document on "Reform on Price Formation Mechanism for Medicine and Medical Services" right after the reform plan?  What will be the next development to the medical device especially with the specific highlight on high value consumables in the consultation document? The presentation will try putting the bits and pieces of information together and discussing the likely impact to medical device industry.

4. Quality Management under Healthcare Reform – Pharma focused
by Ms. Cherrie Che, Senior Manager, Ernst & Young

Ernst & Young recently collaborated with the China Association of Enterprises with Foreign Investment R&D-based Pharmaceutical Association Committee (RDPAC) in a pharmaceutical quality project. The project outlined the importance of patient-centered drug quality and safety issues as well as the needs to enhance China’s global competitiveness in the pharmaceutical industry.  It was also demonstrated that although there have been improvements in the quality of pharmaceutical manufacturing; significant quality gaps still exist in China due to varying quality systems in place and varying levels of GMP enforcement.  The project also emphasized that quality is achievable, but it requires serious commitments, extensive investments, on-going monitoring by manufacturers and onsite inspections by regulatory authority throughout the product life-cycle. Broader concept of cost is associated with not only manufacturing costs, but also activity-based drug quality management related costs. An industry incentive program that encourages continuous quality improvement by rewarding premium quality with a premium price will benefit all stakeholders of the pharmaceutical industry.

5. Promoting a robust, sustainable health insurance market in China
by Mr. Anting Tao, Senior Vice President of Business Development, Strategy Development and External Affairs, WellPoint China

Agenda

13:30 – 14:00    Registration with Coffee and Tea

14:00 – 14:30    Health care reform and implications for Business by Prof. Zhang Wei, Assistant Professor of Management, CEIBS

14:30–15:00      Unlocking China‘s Medical Device Market Potential Brought by the Chinese Healthcare Reform by Mr. Glenn Hou, Consulting Director China, Healthcare, Frost & Sullivan

15:00 – 15:30    Coffee Break

15:30 – 16:00    Medical Device Pricing Reform - Is it the Next by Mr. Camon Sin, Director, Healthcare Economics, Greater China, Medtronic

16:00 – 16:03    Quality Management under Healthcare Refore by Ms. Cherrie Che, Senior Manager, Ernst & Young                

16:30 – 17:00    Promoting a robust, sustainable health insurance market in China by Mr. Anting Tao, Senior Vice President of Business Development, Strategy Development and External Affairs, WellPoint China

17:00 – 17:30    Q&A

17:30 -              Networking

Event Terms & Conditions

Please be advised that the media is normally allowed to attend all EUCCC public events unless otherwise stated, on the condition that no one attending these events quotes participants by name (the "Chatham House Rules").To register for this event please register online by 18:00 7th September, 2009. Please note that we will send you a registration confirmation. We require 24 hours notice for cancellations, no-shows who fail to cancel before this time will be invoiced for the event. Registrations done after the deadline will be accepted only if space permits and are charged an additional 50 RMB walk-in fee. To register this event, please contact Mr. Scott Goodfellow at sgoodfellow@euccc.com.cn

See original information here

Warning：The use of any news and articles published on eChinacities.com without written permission from eChinacities.com constitutes copyright infringement, and legal action can be taken.